Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia

NCT02477670 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

145

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: AVP-786
DRUG: Placebo

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.